These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27863422)

  • 1. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma.
    Pessetto ZY; Chen B; Alturkmani H; Hyter S; Flynn CA; Baltezor M; Ma Y; Rosenthal HG; Neville KA; Weir SJ; Butte AJ; Godwin AK
    Oncotarget; 2017 Jan; 8(3):4079-4095. PubMed ID: 27863422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
    Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
    PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
    Goss KL; Gordon DJ
    Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
    Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
    Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.
    Loganathan SN; Tang N; Holler AE; Wang N; Wang J
    Mol Cancer Ther; 2019 May; 18(5):929-936. PubMed ID: 30926641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.
    Iniguez AB; Stolte B; Wang EJ; Conway AS; Alexe G; Dharia NV; Kwiatkowski N; Zhang T; Abraham BJ; Mora J; Kalev P; Leggett A; Chowdhury D; Benes CH; Young RA; Gray NS; Stegmaier K
    Cancer Cell; 2018 Feb; 33(2):202-216.e6. PubMed ID: 29358035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
    Nan X; Wang J; Cheng H; Yin Z; Sheng J; Qiu B; Lau CC; Yustein JT; Zhao H; Wong STC
    Cancer Lett; 2020 Jan; 469():195-206. PubMed ID: 31672491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma.
    Jess J; Sorensen KM; Boguslawski EA; Stout MC; Madaj ZB; Caiello BP; Pomaville M; Wilson ER; Kinn-Gurzo SS; Parker CC; Veluvolu SM; Brysgel TV; Kaufman R; Kitchen-Goosen SM; Gedminas JM; Grohar PJ
    Clin Cancer Res; 2024 Aug; 30(16):3533-3548. PubMed ID: 38506712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
    Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
    Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma hydrogenated cationic detonation nanodiamonds efficiently deliver to human cells in culture functional siRNA targeting the Ewing sarcoma junction oncogene.
    Bertrand JR; Pioche-Durieu C; Ayala J; Petit T; Girard HA; Malvy CP; Le Cam E; Treussart F; Arnault JC
    Biomaterials; 2015 Mar; 45():93-8. PubMed ID: 25662499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary Hepatic Ewing Sarcoma With EWS-FLI1 RNA Transcript in a Child.
    Pochon C; Martelli H; Mussini C; Pariente D; Heymann MF; Corradini N
    J Pediatr Hematol Oncol; 2015 Jul; 37(5):411-3. PubMed ID: 25411865
    [No Abstract]   [Full Text] [Related]  

  • 13. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
    Prieur A; Tirode F; Cohen P; Delattre O
    Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
    Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
    Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities.
    Radic-Sarikas B; Tsafou KP; Emdal KB; Papamarkou T; Huber KV; Mutz C; Toretsky JA; Bennett KL; Olsen JV; Brunak S; Kovar H; Superti-Furga G
    Mol Cancer Ther; 2017 Jan; 16(1):88-101. PubMed ID: 28062706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ewing's sarcoma: standard and experimental treatment options.
    Subbiah V; Anderson P; Lazar AJ; Burdett E; Raymond K; Ludwig JA
    Curr Treat Options Oncol; 2009 Apr; 10(1-2):126-40. PubMed ID: 19533369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
    Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
    Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.
    Tilan JU; Krailo M; Barkauskas DA; Galli S; Mtaweh H; Long J; Wang H; Hawkins K; Lu C; Jeha D; Izycka-Swieszewska E; Lawlor ER; Toretsky JA; Kitlinska JB
    Cancer; 2015 Mar; 121(5):697-707. PubMed ID: 25387699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poison-Exon Inclusion in DHX9 Reduces Its Expression and Sensitizes Ewing Sarcoma Cells to Chemotherapeutic Treatment.
    Palombo R; Verdile V; Paronetto MP
    Cells; 2020 Jan; 9(2):. PubMed ID: 32023846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.